CAR T cells produce high response rates in ALL, but concerns about side effects remain

October 7, 2016
Novel research has demonstrated that treating acute lymphoblastic leukemia with chimeric antigen receptor T cells produces effective response rates…

Tyrosine kinase inhibitors lead to ‘dramatic’ improvements in CML

September 28, 2016
The development of tyrosine kinase inhibitors for chronic myeloid leukemia, including imatinib, was spurred by an increased understanding of the…

Pediatric regimens for ALL show promise in adults

August 25, 2016
There are several areas of research interest related to the management of young adults with acute lymphoblastic leukemia that stand to impact these…

Identification of biomarkers may allow for better management of GVHD

August 17, 2016
The management of graft-versus-host disease is associated with “multiple problems,” according to James L. M. Ferrara, MD, DSc, of…

Progress in GVHD management improves efficacy of allogeneic HSCT

August 10, 2016
The use of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia has come “a long way in the past 5 to 10…

Checkpoint inhibitor therapy more economical, safe than CAR T cells in pediatric leukemia

July 28, 2016
Novel advances in the use of checkpoint inhibitors – such as an anti-PD1 or anti-PDL1 – to treat pediatric leukemia may result in the…

Ibrutinib, idelalisib, venetoclax provide ‘very exciting developments’ in CLL

July 27, 2016
Recent discoveries involving ibrutinib, idelalisib and venetoclax have had a tremendous impact on life expectancy and quality of life in patients…
Video

VIDEO: James L. M. Ferrara, MD, DSc, reviews “long-standing problem” of GVHD after allogeneic HSCT

July 14, 2016
Graft-versus-host disease is “the major complication” associated with allogeneic hematopoietic stem cell transplantation for the…
Video

VIDEO: Development of tumor lysis syndrome with venetoclax leads to dose ramp-up schedule

July 5, 2016
The occurrence of tumor lysis syndrome in the clinical trial that led to approval of venetoclax for relapsed CLL with deletion of 17p has resulted in…
Video

VIDEO: Development of CAR T-cell therapy shifts from lymphoid to myeloid malignancies

June 2, 2016
The emergence of CAR T-cell therapy for diffuse large B-cell lymphoma and acute lymphocytic leukemia is “a really exciting development”…